Join us this Thursday, 2/27, for an exciting look at the next generation of blood-based predictive biomarkers for therapy selection.

Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment benefit in metastatic malignant melanoma

Get in touch